Napo Pharmaceuticals, Inc

('Napo' or 'the Company')

CANCELLATION OF LISTING

South San Francisco, California, 16 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) announces that its listing on the Official List of the London Stock Exchange will be cancelled effective at 8:00 am 16 October 2008.

Following this notification it is not anticipated that Napo shares will be traded on any public market. 

For more information please contact: 

Napo Pharmaceuticals, Inc. 
Lisa Conte, Chief Executive Officer 
+001 (650) 616-1902 

Charles Thompson, Chief Financial Officer
+001 (650) 616-1902 

Buchanan Communications 
Tim Anderson, Mary-Jane Johnson, Catherine Breen
(44) + 020 7466 5000 

About Napo Pharmaceuticals, Inc. 

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India. 

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program: 

•   CRO-HIV for AIDS diarrhea, Phase 3 
•   CRO-IBS for diarrhea irritable bowel syndrome ('D-IBS'), Phase 2 
•   CRO-ID for acute infectious diarrhea (including cholera), Phase 2 
•   CRO-PED for pediatric diarrhea, Phase 1 

The FDA has granted fast-track status to CRO-IBS and CRO-HIV. 

Crofelemer, a proprietary patented first in class agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo has exclusive worldwide rights to synthetic compounds in pre-clinical development which act by the same mechanism of action. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome) and has 4 issued patents for anti-cancer agents in pre-clinical development. Napo has a plant library of approximately 2,300 medicinal plants from tropical regions and Napo has entered two screening relationships associated with this collection. Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources. 

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. For more information please visit www.napopharma.com. 

This announcement contains forward-looking statements relating to Napo Pharmaceuticals and its products that involve risks and uncertainties, including statements regarding future products and developments that are not historical facts. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. These statements can be identified by the use of forward-looking terminology such as 'believe,' 'expect,' 'may,' 'will,' 'should,'' 'could,' 'project,' 'plan,'' 'seek,' 'intend,'' or 'anticipate'' or the negative thereof or comparable terminology and statements about industry trends and Napo's future performance, operations and products.